Want to see CRSP full AI Analyst Report?
CRSP Stock Chart & Stats
$57.99
-$0.92(-2.19%)
At close: 4:00 PM EST
$57.99
-$0.92(-2.19%)
Day’s Range― - ―
52-Week Range$44.12 - $78.48
Previous CloseN/A
Volume437.82K
Average Volume (3M)1.71M
Market Cap
$5.71B
Enterprise Value$5.48B
Total Cash (Recent Filing)$2.44B
Total Debt (Recent Filing)$787.64M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Aug 10, 2026EPS Estimate
-1.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.22
Shares Outstanding96,448,790
10 Day Avg. Volume1,754,428
30 Day Avg. Volume1,713,343
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.45
Price to Sales (P/S)1343.50
P/FCF Ratio-13.63
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue1.34K
Enterprise Value/Gross Profit-24.94
Enterprise Value/Ebitda-10.04
Forecast
1Y Price Target
$73.85Price Target Upside27.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)-4.84
Revenue Forecast (FY)$37.22M
Bulls Say, Bears Say
Bulls Say
Strategic Partnership With VertexCRISPR’s long-term commercial exposure is meaningfully de‑risked by a major partnership with Vertex around exa‑cel (CASGEVY). Milestone and commercial economics create contingent, durable revenue streams tied to development and approvals, aligning incentives and lowering solo commercialization burden.
Enhanced Liquidity From Convertible OfferingThe upsized $600M convertible raise materially bolsters near-term funding and runway for clinical programs, reducing near-term financing pressure. This provides durable support for R&D execution and regulatory timelines, though it changes capital structure dynamics rather than addressing profitability.
Shareholder-approved Incentive Plan And Governance StabilityApproval of a refreshed incentive plan and re-election of board/auditor signals governance continuity and stronger ability to attract/retain senior scientific and commercial talent. Stable leadership and compensation alignment support long‑term program execution and organizational stability.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flow means the company remains dependent on external financing to fund development. Over multiple quarters this elevates dilution and refinancing risk if clinical or regulatory milestones slip, and limits ability to self-fund commercial scale-up without partners.
Weak Profitability And Small Revenue BaseVery small revenue and deeply negative margins indicate the business is far from breakeven; profitability is volatile. Long development timelines and high R&D spend mean extended periods of losses, raising execution risk and making sustained investment returns contingent on few pipeline successes.
Rising Leverage And Capital Structure RiskMeaningfully higher leverage increases refinancing and interest risks and can constrain strategic options. Combined with ongoing losses, higher debt (including convertibles) may force dilutive financings or limit ability to invest opportunistically, amplifying execution risk if clinical timelines delay.
Crispr Therapeutics AG News
CRSP FAQ
What was Crispr Therapeutics’s price range in the past 12 months?
Crispr Therapeutics lowest stock price was $44.12 and its highest was $78.48 in the past 12 months.
What is Crispr Therapeutics’s market cap?
Crispr Therapeutics’s market cap is $5.71B.
When is Crispr Therapeutics’s upcoming earnings report date?
Crispr Therapeutics’s upcoming earnings report date is Aug 10, 2026 which is in 31 days.
How were Crispr Therapeutics’s earnings last quarter?
Crispr Therapeutics released its earnings results on May 04, 2026. The company reported -$1.28 earnings per share for the quarter, missing the consensus estimate of -$1.218 by -$0.062.
Is Crispr Therapeutics overvalued?
According to Wall Street analysts Crispr Therapeutics’s price is currently Undervalued.
Does Crispr Therapeutics pay dividends?
Crispr Therapeutics does not currently pay dividends.
What is Crispr Therapeutics’s EPS estimate?
Crispr Therapeutics’s EPS estimate is -1.2.
How many shares outstanding does Crispr Therapeutics have?
Crispr Therapeutics has 96,448,790 shares outstanding.
What happened to Crispr Therapeutics’s price movement after its last earnings report?
Crispr Therapeutics reported an EPS of -$1.28 in its last earnings report, missing expectations of -$1.218. Following the earnings report the stock price went down -2.24%.
Which hedge fund is a major shareholder of Crispr Therapeutics?
Currently, no hedge funds are holding shares in CRSP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Crispr Therapeutics AG Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$73.85 (27.34% Upside)
$73.85 (27.34% Upside)
Blogger Sentiment
Bullish
CRSP Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 668.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.98%
12-Months-Change
Fundamentals
Return on Equity
-30.88%
Trailing 12-Months
Asset Growth
25.84%
Trailing 12-Months
Company Description
Crispr Therapeutics
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
CRSP Stock 12 Month Forecast
Average Price Target
$73.85
▲(27.34% Upside)
Technical Analysis
Ownership Overview
2.54% Insiders
13.62% Mutual Funds
0.18% Other Institutional Investors
64.18% Public Companies and Individual Investors